



MORAN ♦ EDWARDS
ASSET MANAGEMENT GROUP
OF WELLS FARGO ADVISORS

Despite recent signs that overall R&D productivity is on the rise again, research released by the Biotechnology Innovation Organization indicates that approximately 90% of all drugs entering a phase 1 clinical trial will fail to gain market approval and this failure rate is trending higher.

Source: FactSet

0818-02162